Pharmaceutical

BGB-30813 by BeiGene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

BGB-30813 is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).

Dec 26, 2023 - 18:00
BGB-30813 is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC).
Read the original article

Tags:

Previous Article

ORB-011 by Orionis Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC):...

Next Article

NT-175 by Neogene Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC):...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Influenza vaccine 2 by Shanghai Institute of Biological...

Jun 11, 2023

AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist

AZ to terminate once-daily cotadutide program to focus ...

Apr 22, 2023

Talaris Therapeutics to merge with Tourmaline Bio

Talaris Therapeutics to merge with Tourmaline Bio

Jun 23, 2023